NOT KNOWN FACTUAL STATEMENTS ABOUT ABBV-744 PRECLINICAL STUDIES AND RESULTS

In Phase A, members will obtain various doses and schedules of oral ABBV-744 tablet to determine Secure dosing program. More individuals will probably be enrolled in the discovered monotherapy dosign routine. In Segment B, contributors will obtain oral ruxolitinib and ABBV-744 will probably be given as "add-on" therapy. In Section C, participants w